China (Mainland)
Diamondsupplier 
factory supply Rivaroxaban Intermediate CAS NO.898543-06-1
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Rivaroxaban
- edoxaban
- 898543-06-1
Quick Details
- ProName: factory supply Rivaroxaban Intermediat...
- CasNo: 898543-06-1
- Molecular Formula: C15H18
- Appearance: White crystallization
- Application: treating pulmonary embolism and preven...
- DeliveryTime: in two weeks
- PackAge: 25kg/drum
- Port: SHANGHAI BEIJING
- ProductionCapacity: 10 Metric Ton/Day
- Purity: 99.9% by HPLC
- Transportation: AIR SEA TRAIN
- LimitNum: 1 Kilogram
- Moisture Content: ≤0.5%
Superiority
We are very compeitive on Rivaroxaban .Our mfr is Chinese GMP certified for this item with DMF/CEP document.
| Product Name: | (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl |
| Synonyms: | (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl;4-[4-[(5S)-5-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholin-3-one hydrochloride;Rivaroxaban Aminomethyl HCl Impurity;Rivaroxaban-19;4-(4-((S)-5-(Aminomethyl)-2-Oxooxazolidin-3-Yl) Phenyl)Morpholin-3-One Hydrochloride;Rivaroxaban C;Rivaroxaban Impurity 11 HCl;(S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride (Rivaroxaban) |
| CAS: | 898543-06-1 |
| MF: | C14H17N3O4.ClH |
| MW: | 327.76 |
| EINECS: | 618-311-0 |
| Product Categories: | Intermediate of Rivaroxaban;Intermediates |
| Mol File: | 898543-06-1.mol |
| (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl Chemical Properties |
| MSDS Information |
| (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl Usage And Synthesis |
| Uses | Rivaroxaban intermediate. |
Details
| Indications and Usage | Rivaroxaban is an antithrombotic drug and was developed in a collaboration between the German Bayer Pharmaceuticals and American Johnson company. It is different from the traditional antithrombotic drug heparin in that Rivaroxaban does not need the participation of antithrombin III and can directly antagonize free and bound Xa factors. Heparin requires the effects of antithrombin III, and has no effect on Xa factors in the prothrombin complex. Rivaroxaban is the first oral direct Xa factor inhibitor in the whole world, and it can selectively and competitively inhibit free and bound Da factors as well as prothrombin activity. It uses a dose-dependent method to extend the partial thromboplastin time (PTT) and activated partial thromboplastin time (aPTT) to extend clotting time and lower thrombin genesis. Rivaroxaban has the characteristics of high bioavailability, wide range of target diseases, stable dose-effect relationship, easy oral intake, and low bleeding risk. Rivaroxaban can also prevent and treat venous thrombosis. It is mainly used clinically to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients following hip and knee replacement surgery. It is also used to prevent patients with nonvalvular atrial fibrillation from cerebral apoplexy and noncentral nervous system embolism, and it can lower the recurrence risk of coronary syndromes. |